Update shared on13 Sep 2025
Fair value Increased 1.00%Tempus AI’s consensus future P/E and discount rate held steady with minimal movement, supporting only a slight upward revision in fair value from $72.73 to $73.45.
What's in the News
- Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform, which now enables generation of T1 and T2 inline maps for enhanced cardiac MR image analysis, supporting more precise and efficient diagnostics.
- The company published a landmark study validating the clinical utility of its PurIST algorithmic diagnostic for advanced pancreatic cancer, showing that integrating PurIST into clinical care improves selection of chemotherapy regimens and patient survival outcomes.
- Northwestern Medicine expanded its collaboration with Tempus to integrate "David," Tempus' generative-AI clinical co-pilot, directly into its EHR platform, streamlining clinical workflows and real-time AI-driven insights for providers.
- Tempus AI expanded its exclusive commercialization agreement with Personalis to include colorectal cancer in the NeXT Personal MRD test partnership, with the exclusivity and contract terms extended through 2029.
- Tempus AI announced a $500 million follow-on equity offering and raised its 2025 revenue guidance to approximately $1.26 billion, representing about 82% annual growth, but also faces a class action lawsuit alleging misstatements related to contracts, financials, and business practices, which triggered a significant share price decline.
Valuation Changes
Summary of Valuation Changes for Tempus AI
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $72.73 to $73.45.
- The Future P/E for Tempus AI remained effectively unchanged, moving only marginally from 64.50x to 65.22x.
- The Discount Rate for Tempus AI remained effectively unchanged, moving only marginally from 7.26% to 7.30%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.